Phase I open-label, multicenter, dose-escalation clinical study of the safety and pharmacokinetic profiles of weekly intravenous administrations of SNS-595 [voreloxin] in patients with advanced malignancies

Trial Profile

Phase I open-label, multicenter, dose-escalation clinical study of the safety and pharmacokinetic profiles of weekly intravenous administrations of SNS-595 [voreloxin] in patients with advanced malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 09 May 2007

At a glance

  • Drugs Vosaroxin (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Jan 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top